The dorsal skin of 6-8-week-old female mice was shaved with electric clippers, and received a first topical application of 8.1 nmol TPA (Sigma-Aldrich) in 200 μl acetone 48 h after being shaved. The mice were treated with TPA a further five times at 48 h intervals. Acetonetreated mice were used as controls. Mice were sacrificed and assessed 48 h after the final TPA treatment.
Immunohistochemistry
The primary antibodies used in the supplementary immunohistochemistry experiments were: rabbit polyclonal anti-TGFBRI (V-22) and anti-TGFBRII (C-16) antibodies (Santa Cruz Biotechnology); mouse monoclonal anti-CD109 (C-9) and anti-p21 (F-5) antibodies (Santa Cruz Biotechnology); rabbit monoclonal anti-TNF-α (D2D4) and anti-pSMAD2 (138D4) antibodies (Cell Signaling Technology); and rabbit polyclonal anti-GM-CSF (ag12142) antibody (Proteintech Group Inc., Rosemont, IL).
Clodronate treatment
Clophosome-A clodronate liposomes (clodronate liposomes) and placebo control liposomes for Clophosome-A (control liposomes) were purchased from FormuMax Scientific Inc. (Sunnyvale, CA). Liposomes (200 μL) were subcutaneously injected into 6-8-week-old female mice on days 0, 2 and 4 of the experiment. Mice were sacrificed 14 days after the first application.
Western blot analysis
The primary antibodies used in the supplementary western blotting experiments were: rabbit monoclonal anti-Gsta3 antibody (Abcam), rabbit polyclonal antiSlc7a11 antibody (Abcam), mouse monoclonal antiNqo1(A180) antibody (Santa Cruz Biotechnology) and rabbit polyclonal anti-Cbr1 antibody (Abcam). 
RNA interference

DNA microarray analysis
CD109
+/+ and CD109 −/− mice were treated with DMBA, and sacrificed 24 h after the treatment. Total RNA was extracted from the skins of the untreated and DMBAtreated CD109 +/+ and CD109 −/− mice using TRIzol (Thermo Fisher Scientific) and an RNeasy Mini Kit (Qiagen) (n = 2 per group; 8 mice in total). Cyanine-3 (Cy3)-labeled cRNA was prepared from 100 ng total RNA using a Low Input Quick Amp Labeling Kit, One-Color (Agilent Technologies). Fragmentation of Cy3-labeled cRNA and hybridization to SurePrint G3 Mouse GE 8×60K Microarray were performed by CDM Center (Takara Bio Inc., Kusatsu, Japan). The data have been deposited in the Gene Expression Omnibus (GEO; accession number GSE87390). (B) and CD109 −/− (C) keratinocytes measured by WST-1 assay in the presence of DMBA (20 μg/ml, n = 3 per group). Cells were pretreated with PBS only (control), TGF-β 1 (10 ng/ml) or SB431542 (TGFBRI inhibitor, 10 ng/ml) for 24 h before incubation with DMBA. D.
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Viability of CD109
+/+ and CD109 −/− keratinocytes transfected with siRNA targeting p21, measured by WST-1 assay in the presence of DMBA (10 μg/ml, n = 3 per group). Cells were pretreated with PBS only (control) or TGF-β 1 (10 ng/ml) for 24 h before incubation with DMBA. E. Effects of siRNA on p21 expression in keratinocytes. CDDP, cisplatin; n.s., not significant; *P < 0.05; **P < 0.01. levels. C. Immunoblot analysis of whole-skin lysates from CD109 +/+ and CD109 −/− mice using antibodies against CD109, Gsta3, Slc7a11, Nqo1 and Cbr1 (n = 3 per group). Expression of β-actin is shown as a loading control. n.s., not significant; *P < 0.05; **P < 0.01. Immunohistochemical staining using antibodies against TGF-β1 (left) and Nrf2 (right) in CD109 +/+ and CD109 −/− skins at 0 (no treatment), 5, and 9 weeks after DMBA initiation. Scale bars, 50 μm. B. Number of Nrf2-positive cells in epidermis per mm of basement membrane (BM) at 0, 5 or 9 weeks after DMBA initiation (n = 3 per group). *P < 0.05; n.s., not significant. Pleural metastasis 1 (6%) 1 (8%) Liver 1 (6%) 0 (0%) Heart (Tumor embolism) 1 (6%) 0 (0%) a) Malignant conversion rate = total number of invasive tumors/total number of tumors b) SCCs, squamous cell carcinomas
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